Göran M Ahlgren1, Per Flodgren2, Teuvo L J Tammela3, Pirkko Kellokumpu-Lehtinen4, Michael Borre5, Anders Angelsen6, Jon Reidar Iversen7, Asgerdur Sverrisdottir8, Eirikur Jonsson9, Lisa Sengelov10. 1. Department of Urology, Lund University, Skåne University Hospital, Sweden. Electronic address: goran.ahlgren@med.lu.se. 2. Department of Oncology, Lund University, Skåne University Hospital, Sweden. 3. Department of Urology, University of Tampere, Tampere University Hospital, Finland. 4. Department of Oncology, University of Tampere, Tampere University Hospital, Finland. 5. Department of Urology, Aarhus University Hospital, Skejby Sygehus, Denmark. 6. Department of Urology, Norwegian University of Science and Technology, Trondheim, Norway. 7. Department of Oncology, Oslo University Hospital, Norway. 8. Department of Oncology, Landspitali University Hospital, Reykjavik, Iceland. 9. Department of Urology, Landspitali University Hospital, Reykjavik, Iceland. 10. Department of Oncology, Herlev-Gentofte Hospital, Herlev, Denmark.
Abstract
BACKGROUND:Adjuvant chemotherapy is standard treatment for other solid tumours, but to date has not proven effective in prostate cancer. OBJECTIVE: o evaluate whether six cycles of docetaxel alone improve biochemical disease-free survival after radical prostatectomy for high-risk prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: Open-label, randomised multinational phase 3 trial. Enrolment of 459 patients after prostatectomy. INCLUSION CRITERIA: high-risk pT2 margin positive or pT3a Gleason score ≥4+3, pT3b, or lymph nodepositive disease Gleason score ≥3+4. Patients assigned (1:1) to either six cycles of adjuvant docetaxel 75mg/m2 every 3 wk without daily prednisone (Arm A) or surveillance (Arm B) until endpoint was reached. Primary endpoint was prostate-specific antigen progression ≥0.5 ng/ml. INTERVENTION: Docetaxel treatment after prostatectomy. RESULTS AND LIMITATIONS: Median time to progression, death, or last follow-up was 56.8 mo. Primary endpoint was reached in 190/459 patients-the risk of progression at 5 yr being 41% (45% in Arm A and 38% in Arm B). There was evidence of nonproportional hazards in Kaplan-Meier analysis, so we used the difference in restricted mean survival time as the primary estimate of effect. Restricted mean survival time to endpoint was 43 mo in Arm A versus 46 mo in Arm B (p=0.06), a nonsignificant difference of 3.2 mo (95% confidence interval: 6.7 to -1.5 mo). A total of 116 serious adverse events were recorded in Arm A and 41 in Arm B with no treatment-related deaths. Not all patients received docetaxel by protocol. The endpoint is biochemical progression and some patients received radiation treatment before the endpoint. CONCLUSIONS:Docetaxel without hormonal therapy did not significantly improve biochemical disease-free survival after radical prostatectomy. PATIENT SUMMARY: In this randomised trial, we tested whether chemotherapy after surgery for high-risk prostate cancer decreases the risk of a rising prostate-specific antigen. We found no benefit from docetaxel given after radical prostatectomy.
RCT Entities:
BACKGROUND: Adjuvant chemotherapy is standard treatment for other solid tumours, but to date has not proven effective in prostate cancer. OBJECTIVE: o evaluate whether six cycles of docetaxel alone improve biochemical disease-free survival after radical prostatectomy for high-risk prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: Open-label, randomised multinational phase 3 trial. Enrolment of 459 patients after prostatectomy. INCLUSION CRITERIA: high-risk pT2 margin positive or pT3a Gleason score ≥4+3, pT3b, or lymph node positive disease Gleason score ≥3+4. Patients assigned (1:1) to either six cycles of adjuvant docetaxel 75mg/m2 every 3 wk without daily prednisone (Arm A) or surveillance (Arm B) until endpoint was reached. Primary endpoint was prostate-specific antigen progression ≥0.5 ng/ml. INTERVENTION: Docetaxel treatment after prostatectomy. RESULTS AND LIMITATIONS: Median time to progression, death, or last follow-up was 56.8 mo. Primary endpoint was reached in 190/459 patients-the risk of progression at 5 yr being 41% (45% in Arm A and 38% in Arm B). There was evidence of nonproportional hazards in Kaplan-Meier analysis, so we used the difference in restricted mean survival time as the primary estimate of effect. Restricted mean survival time to endpoint was 43 mo in Arm A versus 46 mo in Arm B (p=0.06), a nonsignificant difference of 3.2 mo (95% confidence interval: 6.7 to -1.5 mo). A total of 116 serious adverse events were recorded in Arm A and 41 in Arm B with no treatment-related deaths. Not all patients received docetaxel by protocol. The endpoint is biochemical progression and some patients received radiation treatment before the endpoint. CONCLUSIONS:Docetaxel without hormonal therapy did not significantly improve biochemical disease-free survival after radical prostatectomy. PATIENT SUMMARY: In this randomised trial, we tested whether chemotherapy after surgery for high-risk prostate cancer decreases the risk of a rising prostate-specific antigen. We found no benefit from docetaxel given after radical prostatectomy.
Authors: Seth A Rosenthal; Chen Hu; Oliver Sartor; Leonard G Gomella; Mahul B Amin; James Purdy; Jeff M Michalski; Mark G Garzotto; Nadeem Pervez; Alexander G Balogh; George B Rodrigues; Luis Souhami; M Neil Reaume; Scott G Williams; Raquibul Hannan; Eric M Horwitz; Adam Raben; Christopher A Peters; Felix Y Feng; William U Shipley; Howard M Sandler Journal: J Clin Oncol Date: 2019-03-12 Impact factor: 50.717
Authors: Ketevan Paliashvili; Francesco Di Maggio; Hei Ming Kenneth Ho; Sanjayan Sathasivam; Hashim Ahmed; Richard M Day Journal: Drug Deliv Date: 2019-12 Impact factor: 6.419
Authors: R Kanesvaran; E Castro; A Wong; K Fizazi; M L K Chua; Y Zhu; H Malhotra; Y Miura; J L Lee; F L T Chong; Y-S Pu; C-C Yen; M Saad; H J Lee; H Kitamura; K Prabhash; Q Zou; G Curigliano; E Poon; S P Choo; S Peters; E Lim; T Yoshino; G Pentheroudakis Journal: ESMO Open Date: 2022-07-04
Authors: Stefan A Koerber; Johannes Boesch; Clemens Kratochwil; Ingmar Schlampp; Jonas Ristau; Erik Winter; Stefanie Zschaebitz; Luisa Hofer; Klaus Herfarth; Klaus Kopka; Tim Holland-Letz; Dirk Jaeger; Markus Hohenfellner; Uwe Haberkorn; Juergen Debus; Frederik L Giesel Journal: Cancers (Basel) Date: 2021-03-25 Impact factor: 6.639